$552,098 Raised for Cancer Research to Fund Four Damon Runyon Scientists

As a result of our 2018 fundraising efforts from the William Raveis Ride + Walk across five states (Connecticut, Massachusetts, New York, Vermont and Florida), we have raised $552,098 with 100% going to these four Damon Runyon Scientists. Please read about the 2019 William Raveis Charitable Fund Fellowships and about their brilliant and groundbreaking cancer research.

2019 William Raveis Charitable Fund Scientists

Vinod Balachandran, MD, Clinical Investigator, Memorial Sloan Kettering Cancer Center: Pancreatic cancer

Despite our best current treatments, 95% of patients with pancreatic cancer, including those at the earliest stages, die within 5 years of diagnosis. By 2020, pancreatic cancer will become the second leading cause of cancer-related death in the U.S. New therapies are urgently needed. T cells are highly specialized cells of the immune system designed to protect the human body from infections and cancer. Very few T cells recognize pancreatic cancer; however, recent work showed that these T cells play a very important role in controlling the spread of pancreatic cancer. Patients whose tumors have higher proportions of T cells survived over 3-times longer than patients who did not. Dr. Balachandran’s group has unique access to these extremely rare patients that survived, on average, 6 years with pancreatic cancer and whose tumors have 12-times as many activated T cells as patients who have more typical poor outcomes. He has discovered that their exceptional survival is linked to T cells recognizing novel cancer proteins that make these cancers resemble infections. His research will focus on understanding these unique cancer proteins in long-term survivors, with the goal of developing novel immunotherapies to treat all patients with pancreatic cancer.

Dr. Balachandran earned his undergraduate degree in physics from Cornell University, and his MD from SUNY Stony Brook. When he is not in the lab, he enjoys classical violin and percussion, endurance running and triathlons.  He speaks Mandarin Chinese, Tamil, Malayalam, and Hindi.

Adrienne Boire, MD, PhD Clinical Investigator, Memorial Sloan Kettering Cancer Center: Neuro-oncology

Leptomeningeal metastasis, or spread of cancer cells into the spinal fluid, is a devastating complication of cancer resulting in rapid neurologic disability and death. With little mechanistic information to guide treatment decisions, efforts at treatment are too often futile. To address this critical knowledge gap, Dr. Boire will employ a translational approach to analyze patient samples utilizing multiple, complementary, orthogonal molecular strategies as tools for discovery. This approach will be coupled with hypothesis-driven mouse models to assemble coherent molecular mechanisms that describe cancer cell interactions with their microenvironment. This mechanistic work will suggest new targets for therapeutic intervention, paving the way for novel treatment approaches.

Dr. Boire was raised in Minnesota where she attended Macalester College, earning an undergraduate degree in biology. She later earned a PhD in biochemistry from Tufts University and her MD from the University of Chicago. Dr. Boire’s patients inspire her to see the beauty in everyday life.  She and her family make time to visit the many museums near their home in New York.  She is particularly fascinated by still life: art that elevates the everyday into the extraordinary. For her, art demands that we stop, consider and appreciate the luminous and evanescent spectacle of everyday life unfolding around us.

Lillian Guenther, MD. Physician-Scientist, Dana-Farber Cancer Institute Pediatric, Sarcoma Photo by Sam Ogden.

Ewing sarcoma is an aggressive bone tumor that occurs in children and young adults. Cure rates, particularly when disease has spread, are low with currently available treatments. Dr. Guenther aims to identify critical genes on which Ewing sarcoma cells are dependent for survival, with the goal of discovering weaknesses in these cancer cells that may be exploited to stop cancer growth. CITED2 is of particular interest as a Ewing sarcoma-specific dependency gene based on a genome-wide screen in hundreds of cancer cell lines. Her goal is to develop new directed cancer therapies for patients with this devastating disease. She hopes that these studies will have an additional impact on the treatment of other cancers where CITED2 has been shown to play a role, including acute myeloid leukemia.

Dr. Guenther completed her undergraduate studies at Brown University in 2005, where she received a Bachelor of Arts degree in History. She then went on to receive her M.D. degree from the State University of New York Downstate Medical Center College of Medicine in 2011, where she received awards for distinguished performance in Pediatrics and Medical Humanities. Dr. Guenther completed her General Pediatrics Internship and Residency in the Boston Combined Residency Program in 2014 and completed her Fellowship in Pediatric Hematology/Oncology at Dana Farber Cancer Institute and Boston Children’s Hospital in 2017. When not in lab or in clinic, Dr. Guenther is an avid distance runner, enjoys crossword puzzles, reading, and listening to live music as well as playing the violin. She enjoys traveling around the world as well as spending time exploring New England with her family and friends.

Harshabad Singh, MBBS, Physician-Scientist, Dana-Farber Cancer Institute: Gastric

Cancers involving the lower esophagus (esophageal adenocarcinomas) have dramatically increased in number over the last several decades. The reason for rise in this cancer is not completely understood. However, long before these esophageal cancers arise the normal esophageal multilayered squamous lining (or epithelium) is replaced by a single layered columnar epithelium which has features similar to the lining of the intestine and is known as Barrett’s esophagus. Dr. Singh proposes to investigate the origins and factors governing the genesis of Barrett’s esophagus and understand its specific vulnerability to progress to cancer. This work will yield insights into disease mechanisms and reveal novel preventive strategies for esophageal adenocarcinomas.

Dr. Singh received his medical degree from Punjab University, Chandigarh, India. He credits his family, many of whom are physicians, as his inspiration for attending medical school.  He completed his training at Massachusetts General Hospital, where he received the Senior Resident Excellence in Teaching Award.  Outside of the laboratory, he enjoys watching cricket, spending time with his wife and 2-year old son and exploring New England.


(Visited 284 times, 1 visits today)